Cargando…
Final 5‐Year Report of the Randomized BIO‐RESORT Trial Comparing 3 Contemporary Drug‐Eluting Stents in All‐Comers
BACKGROUND: In a previous trial, higher 5‐year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus‐eluting stents (SES). We assessed 5‐year safety and efficacy of all‐comers as well as patients with diabetes treated with SES or Synergy everolimus‐eluting stents (EE...
Autores principales: | Ploumen, Eline H., Pinxterhuis, Tineke H., Buiten, Rosaly A., Zocca, Paolo, Danse, Peter W., Schotborgh, Carl E., Scholte, Martijn, Gin, R. Melvyn Tjon Joe, Somi, Samer, van Houwelingen, K. Gert, Stoel, Martin G., de Man, H. A. F., Hartmann, Marc, Linssen, Gerard C. M., van der Heijden, Liefke C., Kok, Marlies M., Doggen, Carine J. M., von Birgelen, Clemens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750072/ https://www.ncbi.nlm.nih.gov/pubmed/36346050 http://dx.doi.org/10.1161/JAHA.122.026041 |
Ejemplares similares
-
Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials
por: Ploumen, Eline H., et al.
Publicado: (2021) -
Three contemporary thin‐strut drug‐eluting stents implanted in severely calcified coronary lesions of participants in a randomized all‐comers trial
por: Buiten, Rosaly A., et al.
Publicado: (2020) -
Three‐year clinical outcome in all‐comers with “silent” diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug‐eluting stents: From the BIO‐RESORT Silent Diabetes study
por: Ploumen, Eline H., et al.
Publicado: (2019) -
High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
por: Zocca, Paolo, et al.
Publicado: (2018) -
Outcome of percutaneous coronary intervention using ultrathin-strut biodegradable polymer sirolimus-eluting versus thin-strut durable polymer zotarolimus-eluting stents in patients with comorbid peripheral arterial disease: a post-hoc analysis from two randomized trials
por: Pinxterhuis, Tineke H., et al.
Publicado: (2023)